Analysis of the factors motivating HCV-infected patients to accept interferon therapy
Open Access
- 29 August 2012
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 470
Abstract
The aims of this study were to analyze factors motivating the acceptance of interferon (IFN) therapy and to clarify the prevalence of oral mucosal diseases in hepatitis C virus (HCV)-infected Japanese patients treated with IFN. A total of 94 HCV-infected patients who were admitted to our hospital for IFN therapy were asked questions regarding their motivation to accept IFN therapy and were investigated for the presence of oral lichen planus (OLP) before and during IFN treatment. Recommendation and encouragement from other people were the most common factors motivating the acceptance of IFN therapy (49/94, 52.13%). The other motivators were independent decision (30.85%), economic reasons (5.32%), and others. According to multivariate analysis, three factors – sex (male), retreatment after previous IFN therapy, and independent decision to accept IFN therapy - were associated with patients after curative treatment of hepatocellular carcinoma (HCC). The adjusted odds ratios for these three factors were 26.06, 14.17, and 8.72, respectively. The most common oral mucosal lesions included OLP in 11 cases (11.70%). One patient with OLP had postoperative squamous cell carcinoma of the tongue. The rate of sustained virological response (SVR) was 45.45% in cases with OLP and 54.55% in cases without OLP. There were no patients who discontinued IFN therapy because of side effects such as oral mucosal diseases. We should give full explanation and recommend a course of treatment for a patient to accept IFN therapy. The system to support liver disease as well as oral diseases is also necessary for patient treated for IFN therapy.Keywords
This publication has 24 references indexed in Scilit:
- Dental problems delaying the initiation of interferon therapy for HCV-infected patientsVirology Journal, 2010
- Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirinEuropean Journal of Gastroenterology & Hepatology, 2008
- Insulin resistance and lichen planus in patients with HCV‐infectious liver diseasesJournal of Gastroenterology and Hepatology, 2008
- Medical Informed Consent: General Considerations for PhysiciansMayo Clinic Proceedings, 2008
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006
- Extrahepatic Manifestations Associated with Hepatitis C Virus Infection: A Prospective Multicenter Study of 321 PatientsMedicine, 2000
- Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in JapanAnnals of Internal Medicine, 1999
- Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patientsJournal of Hepatology, 1999
- Hepatitis C: A Multifaceted Disease: Review of Extrahepatic ManifestationsAnnals of Internal Medicine, 1995
- Lichen planus and Virus C Hepatitis: Disappearance of the Lichen under Interferon Alfa TherapyDermatology, 1992